Clinical trials: B ALL
Leukemia, Lymphocytic, Chronic, B-Cell
Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
This is a multi-center, Phase II, open label trial evaluating the efficacy and safety of alemtuzumab and fludarabine in the treatment of B-cell chronic lymphocytic leukemia (B-CLL) patients who have received at least one prior…
- Trial name
- ECO-1 (NCT00206726)
- Testing
- Alemtuzumab plus Fludarabine
- Where
- 27 sites in United States
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Yosemite (NCT01732913)
- Testing
- Rituximab, Idelalisib
- Where
- 103 sites in United States, Australia and 17 more
- Volunteers
- 295 people
- Sponsor
- Gilead Sciences
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00049504
- Testing
- cyclophosphamide, fludarabine phosphate, tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphocytic Leukemia, Chronic
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
This multi-center, single-arm study evaluated the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide in participants with B-cell chronic lymphocytic leukemia (CLL) and favorable somatic status.
- Trial name
- NCT01271010
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 10 sites in Russia
- Volunteers
- 89 people
- Sponsor
- Hoffmann-La Roche
Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
- Conditions
- Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS
- Trial name
- NAVAL-1 (NCT05011058)
- Testing
- Nanatinostat in combination with valganciclovir
- Where
- 62 sites in United States, Australia and 12 more
- Volunteers
- 102 people
- Sponsor
- Viracta Therapeutics, Inc.
Multiple Myeloma and Plasma Cell Neoplasm
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma.
- Trial name
- NCT00897910
- Testing
- flow cytometry, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Meningococcal Disease
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.
The purpose of the study was to assess the immunogenicity and safety of two doses of Novartis Meningococcal B Recombinant (rMenB+OMV NZ) vaccine administered one month apart (0, 1 month schedule) in Korean adolescents aged…
- Trial name
- NCT01973218
- Testing
- Meningococcal B Recombinant vaccine rMenB+OMV NZ, Meningococcal ACWY-CRM conjugate vaccine
- Where
- 7 sites in South Korea
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Diffuse Large B-cell Lymphoma
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00474188
- Testing
- CC-5013 (lenalidomide), dexamethasone
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Celgene Corporation
Haemophilus Influenzae Type b, Neisseria Meningitidis
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
The booster phase of the study will evaluate the safety of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine at 12 to 15 months of age.
- Trial name
- NCT00345683
- Testing
- GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar
- Where
- 57 sites in United States, Mexico
- Volunteers
- 4,021 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Severe Insulin Resistance
Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance
Study Description: Patients with mutations of the insulin receptor have diabetes that is challenging to control with conventional therapies, leading to early morbidity and mortality.
- Trial name
- NCT00085982
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond to treatment (refractory).
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Trial name
- NCT03038672
- Testing
- Nivolumab, Varlilumab
- Where
- 33 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
The purpose of this study is to determine the percentage of people who can attain remission and the length of time such responses to therapy are sustained, as well as the side effects that might result from rituximab and…
- Trial name
- NCT00142116
- Testing
- Thalidomide, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Steven P. Treon, MD, PhD
Pancreatic Cancer
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
The investigator is developing an immune therapy against pancreatic cancer. Immune cells, known as "T cells with tumor killing capacity", are involved in this immune therapy.
- Trial name
- NCT03848182
- Testing
- Gemcitabine, TT vaccine booster
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
RATIONALE: A gene-modified virus may be able to kill tumor cells without damaging normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of an attenuated oncolytic measles virus therapy and oncolytic…
- Trial name
- NCT00408590
- Testing
- carcinoembryonic antigen-expressing measles virus, oncolytic measles virus encoding thyroidal sodium iodide symporter, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Mayo Clinic
Acute Leukemia, Chronic Lymphocytic Leukemia
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
This phase II trial studies how well tacrolimus, bortezomib, and anti-thymocyte globulin (thymoglobulin) work in preventing low toxicity graft versus host disease (GVHD) in patients with blood cancer who are undergoing donor stem…
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT02877082
- Testing
- Thymoglobulin, Bortezomib, Tacrolimus
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Diffuse Large B-Cell Lymphoma
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
This multicenter, open-label study will assess the efficacy and safety of MabThera (rituximab) added to standard chemotherapy in participants with untreated Mantle Cell Lymphoma not eligible for autologous stem cell…
- Trial name
- NCT01144403
- Testing
- Cyclophosphamide, Fludarabine, Mitoxantrone
- Where
- 8 sites in Romania
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma…
- Trial name
- NCT05498220
- Testing
- Polatuzumab vedotin (PV), Rituximab, Hyaluronidase
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
ALL, B Cell Lymphoma
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
Background: Although progress has been made in treating children with B-cell cancers such as leukemia or lymphoma, many children do not respond to the standard treatments.
- Conditions
- ALL, B Cell Lymphoma, Leukemia, Large Cell Lymphoma
- Trial name
- NCT01593696
- Testing
- Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Encephalitis, Japanese B
Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
This study will determine whether it is safe and effective to administer Japanese encephalitis (JE) live attenuated SA 14-14-2 vaccine at the same time as measles vaccine.
- Trial name
- NCT00249769
- Testing
- Live Japanese encephalitis vaccine SA 14-14-2 (LJEV), Measles Vaccine (MV)
- Where
- Philippines
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PATH
B-Thalassemia
Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics, of ascending doses of luspatercept in participants with β-thalassemia.
- Trial name
- NCT01749540
- Testing
- luspatercept
- Where
- 8 sites in Greece, Italy
- Volunteers
- 64 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.